Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Waldenstrom Macroglobulinemia × Lisaftoclax × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Leukemia, Myeloid, Acute 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Neuroblastoma 1 Lymphoma, Mantle-Cell 1 Leukemia, Prolymphocytic, T-Cell 1 Leukemia 1 Hematologic Neoplasms 1 Dendritic Cell Sarcoma, Interdigitating 1 Breast Neoplasms 1 Amyloidosis 1

Interventions

Rituximab 99 Cyclophosphamide 63 fludarabine phosphate 54 Peripheral Blood Stem Cell Transplantation 52 Mycophenolic Acid 33 Bortezomib 33 Whole-Body Irradiation 32 ibrutinib 29 Dexamethasone 27 Tacrolimus 25 Cyclosporine 25 Etoposide 22 Busulfan 22 Melphalan 20 Filgrastim 20 Methotrexate 18 Lenalidomide 18 Antilymphocyte Serum 18 Radiotherapy 16 zanubrutinib 14 Bendamustine Hydrochloride 14 Sirolimus 13 Calcium Dobesilate 11 Everolimus 10 ibritumomab tiuxetan 9 Prednisone 9 Cyclosporins 9 venetoclax 8 idelalisib 8 Indium 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡